| 1 |
Wu F，Wang L，Zhou C.Lung cancer in China：Current and prospect［J］.Curr Opin Oncol，2021，33（1）：40-46.
|
| 2 |
吴国明，钱桂生.非小细胞肺癌靶向治疗研究进展及新理念［J/CD］.中华肺部疾病杂志（电子版），2019，12（4）：405-408.
|
| 3 |
Schabath MB，Cote ML.Cancer progress and priorities：Lung cancer［J］.Cancer Epidemiol Biomarkers Prev，2019，28（10）：1563-1579.
|
| 4 |
农靖颖，顾艳斐，张 毅.晚期非小细胞肺癌免疫治疗预测生物标志物的研究进展［J/CD］.中华肺部疾病杂志（电子版），2021，14（4）：536-538.
|
| 5 |
Wu S，Zhu C，Tang D，et al.The role of ferroptosis in lung cancer［J］.Biomark Res，2021，9（1）：82.
|
| 6 |
Yoshida M，Minagawa S，Araya J，et al.Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis［J］.Nat Commun，2019，10（1）：3145.
|
| 7 |
Robinson MD，Mccarthy DJ，Smyth GK.edgeR：a Bioconductor package for differential expression analysis of digital gene expression data［J］.Bioinformatics，2010，26（1）：139-140.
|
| 8 |
Ritchie ME，Phipson B，Wu D，et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies［J］.Nucleic Acids Res，2015，43（7）：e47.
|
| 9 |
Langfelder P，Horvath S.WGCNA：an R package for weighted correlation network analysis［J］.BMC bioinformatics，2008，9（1）：559.
|
| 10 |
Li J，Cao F，Yin H，et al.Ferroptosis：past，present and future［J］.Cell Death Dis，2020，11（2）：88.
|
| 11 |
Badgley MA，Kremer DM，Maurer HC，et al.Cysteine depletion induces pancreatic tumor ferroptosis in mice［J］.Science，2020，368（6486）：85-89.
|
| 12 |
Dai E，Han L，Liu J，et al.Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway［J］.Nat Commun，2020，11（1）：6339.
|
| 13 |
Becker HM.Carbonic anhydrase IX and acid transport in cancer［J］.Br J Cancer，2020，122（2）：157-167.
|
| 14 |
Mcdonald PC，Winum JY，Supuran CT，et al.Recent developments in targeting carbonic anhydrase IX for cancer therapeutics［J］.Oncotarget，2012，3（1）：84-97.
|
| 15 |
Li Z，Jiang L，Chew SH，et al.Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia［J］.Redox Biol，2019，26：101297.
|
| 16 |
Song X，Zhu S，Xie Y，et al.JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice［J］.Gastroenterology，2018，154（5）：1480-1493.
|
| 17 |
Wen J，Yang T，Mallouk N，et al.Urinary exosomal CA9 mRNA as a novel liquid biopsy for molecular diagnosis of bladder cancer［J］.Int J Nanomedicine，2021，16：4805-4811.
|
| 18 |
Gu M.CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma ［J］.Int J Clin Exp Pathol，2015，8（1）：862-866.
|
| 19 |
Guan C，Ouyang D，Qiao Y，et al.CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients［J］.J Cell Mol Med，2020，24（10）：5832-5841.
|
| 20 |
Wang S，Fu Z，Wang Y，et al.Correlation of carbonic anhydrase 9（CA9） with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma［J］.Ann Transl Med，2020，8（22）：1521.
|
| 21 |
Sowa T，Menju T，Chen-Yoshikawa TF，et al.Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression［J］.Cancer Med，2017，6（1）：288-297.
|
| 22 |
Giatromanolaki A，Harris AL，Banham AH，et al.Carbonic anhydrase 9 （CA9） expression in non-small-cell lung cancer：correlation with regulatory FOXP3 + T-cell tumour stroma infiltration ［J］.Br J Cancer，2020，122（8）：1205-1210.
|
| 23 |
Zhang C，Lu X，Liu X，et al.Carbonic anhydrase IX controls vulnerability to ferroptosis in gefitinib-resistant lung cancer［J］.Oxid Med Cell Longev，2023，2023：1367938.
|
| 24 |
Stewart DJ，Nunez MI，Behrens C，et al.Membrane carbonic anhydrase IX expression and relapse risk in resected stage Ⅰ-Ⅱnon-small-cell lung cancer［J］.J Thorac Oncol，2014，9（5）：675-684.
|
| 25 |
Janmaat ML，Rodriguez JA，Jimeno J，et al.Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling［J］.Mol Pharmacol，2005，68（2）：502-510.
|
| 26 |
Wyer S，Townsend DM，Ye Z，et al.Recent advances and limitations in the application of kahalalides for the control of cancer［J］.Biomed Pharmacother，2022，148：112676.
|
| 27 |
Arkenau H，Plummer R，Molife LR，et al.A phase I dose escalation study of AT9283，a small molecule inhibitor of aurora kinases，in patients with advanced solid malignancies［J］.2012，23（5）：1307-1313.
|
| 28 |
Dent SF，Gelmon KA，Chi KN，et al.NCIC CTG IND.181：phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies［J］.Invest New Drugs，2013，31（6）：1522-1529.
|
| 29 |
Lucas M，Lynley VM，Andrew DJP，et al.A phase I trial of AT9283（a selective inhibitor of aurora kinases） in children and adolescents with solid tumors：A Cancer Research UK study［J］.Clin Cancer Res，2015，21（2）：267-273.
|
| 30 |
Moreno L，Marshall LV，Pearson AD，et al.A phase I and pharmacodynamic study of AT9283，a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis［J］.Clin Cancer Res，2015，21（2）：267-273.
|